SP Tulsian of sptulsian.com told CNBC-TV18, "Positive view is continuous on all pharma sectors except Ranbaxy because the kind of concerns which we have been hearing in respect to the Daiichi, their grievances against the erstwhile promoter and may be regulatory actions."
"Apollo Pharmacy has stopped selling drugs of Ranbaxy. All these concerns really seem serious and that will keep the prices under check if not make it fall further. So it is better to exit the stock and look for other ideas like Glenmark Pharma, Aurobindo Pharma or Cipla. These three stocks are better shift from Ranbaxy," Tulsian said. Also Read: Ranbaxy issue resolved, informs Apollo Pharmacy
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
